March 14, 2018 - By Hazel Jackson

The stock of VODIS PHARMACEUTICALS INC ORDINARY SHARE (OTCMKTS:VDQSF) registered a decrease of 91.89% in short interest. VDQSF’s total short interest was 900 shares in March as published by FINRA. Its down 91.89% from 11,100 shares, reported previously. With 4,500 shares average volume, it will take short sellers 0 days to cover their VDQSF’s short positions. The short interest to VODIS PHARMACEUTICALS INC ORDINARY SHARE’s float is 0.01%.

The stock decreased 6.40% or $0.004 during the last trading session, reaching $0.299. About 550 shares traded or Infinity% up from the average. Vodis Pharmaceuticals Inc. (OTCMKTS:VDQSF) has 0.00% since March 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Vodis Pharmaceuticals Inc. operates as an application stage firm for producing medical marijuana. The company has market cap of $11.49 million. It operates in Canada and the United States. It currently has negative earnings.

More notable recent Vodis Pharmaceuticals Inc. (OTCMKTS:VDQSF) news were published by: Investingnews.com which released: “Hydropothecary Announces Results of Shareholders Meeting” on January 18, 2018, also Investingnews.com with their article: “10 Top Canadian Cannabis Stocks” published on October 20, 2016, Investingnews.com published: “CannabisInvesting News” on April 07, 2017. More interesting news about Vodis Pharmaceuticals Inc. (OTCMKTS:VDQSF) were released by: Investingnews.com and their article: “MYM Nutraceuticals Releases Video on its Global Operations” published on February 08, 2018 as well as Investingnews.com‘s news article titled: “Emblem Pharmaceuticals to Invest Significant Capital to Expand Production” with publication date: October 17, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: